MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

450.57
-2.62
-0.58%
After Hours: 451.00 +0.43 +0.10% 19:25 02/26 EST
OPEN
455.84
PREV CLOSE
453.19
HIGH
457.17
LOW
445.57
VOLUME
1.19M
TURNOVER
--
52 WEEK HIGH
664.64
52 WEEK LOW
418.01
MARKET CAP
48.27B
P/E (TTM)
14.69
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster.
Benzinga · 15h ago
Regeneron’s antibody cocktail shows promise in cat-allergic patients with mild asthma
Regeneron Pharmaceuticals (REGN) has announced positive results from a Phase 2 proof-of-concept trial evaluating its investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma.The Phase 2 randomized, double-blind proof-of-con...
Seekingalpha · 1d ago
BRIEF-Regeneron Announces Positive Phase 2 Data Evaluating Fel D 1 Antibody Cocktail In Cat-Allergic Patients With Mild Asthma
reuters.com · 1d ago
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
PR Newswire · 1d ago
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Feb. 26, 2021: TWST, TMO, RHHBY, GOOGL, CDNA, TSM, SNPS, SNAP, ICE, NVS, PINS, REGN, ROKU, FLIR, AMZN, AAPL, FB, CRM, BABA, TCEHY
Twist Bioscience (TWST) - 51,404 Thermo Fisher Scientific (TMO) - 46,642 Roche (RHHBY) - 54,800 Alphabet (GOOGL) - 10,400 CareDx (CDNA) - 101,014 Taiwan Semiconductor Manufacturing (TSM) - 938,701 Synopsys (SNPS)
Benzinga · 2d ago
Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning
Investor's Business Daily · 2d ago
Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market
Shares of Regeneron Pharmaceuticals Inc. slumped 0.58% to $450.57 Friday, on what proved to be an all-around dismal trading session for the stock market,...
marketwatch.com · 2d ago
Regeneron's COVID-19 Antibody Cocktail Wins EU Positive Opinion
Benzinga · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REGN. Analyze the recent business situations of Regeneron Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REGN stock price target is 650.83 with a high estimate of 795.00 and a low estimate of 525.00.
EPS
Institutional Holdings
Institutions: 1.36K
Institutional Holdings: 93.57M
% Owned: 87.34%
Shares Outstanding: 107.13M
TypeInstitutionsShares
Increased
351
4.18M
New
257
-615.99K
Decreased
275
5.18M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
P. Roy Vagelos
President/Chief Executive Officer/Director
Leonard Schleifer
Co-President/Chief Scientific Officer/Director
George Yancopoulos
Chief Financial Officer/Executive Vice President - Finance
Robert Landry
Executive Vice President/General Counsel/Secretary
Joseph LaRosa
Executive Vice President/General Manager
Daniel Van Plew
Executive Vice President
Andrew Murphy
Executive Vice President
Neil Stahl
Senior Vice President
Marion McCourt
Vice President/Controller
Christopher Fenimore
Independent Director
Bonnie Bassler
Independent Director
Michael Brown
Independent Director
N. Anthony Coles
Independent Director
Joseph Goldstein
Independent Director
Christine Poon
Independent Director
Arthur Ryan
Independent Director
George Sing
Independent Director
Marc Tessier-Lavigne
Independent Director
Huda Zoghbi
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About REGN
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.